Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC

Dhillon, S; Syed, YY

Syed, YY (reprint author), Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.

TARGETED ONCOLOGY, 2019; 14 (6): 759

Abstract

Atezolizumab (Tecentriq (R)), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplat......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索